

CORRECTION

Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society

In the special article “Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society” by S.D. Silberstein et al. (*Neurology* 2012;78:1337–1345), there are errors in table 1 and the text on page 1342. Due to changes in the AAN’s LOE classification criteria, pindolol and clonidine should have been labeled as having Level U recommendations and nifedipine and nicardipine should have been listed as having a Level C recommendation. These changes are based on studies cited in the original 2001 guideline; no new studies were found in the literature search for the 2012 update. Please see the corrected table below. The authors regret the errors.

Table 1 Classification of migraine preventive therapies (available in the United States)

Level A: Medications with established efficacy (≥2 Class I trials)	Level B: Medications are probably effective (1 Class I or 2 Class II studies)	Level C: Medications are possibly effective (1 Class II study)	Level U: Inadequate or conflicting data to support or refute medication use	Other: Medications that are established as ineffective, probably ineffective, or possibly ineffective
Antiepileptic drugs	Antidepressants/SSRI/SSNRI/TCA	ACE inhibitors	α-Agonists	Established as ineffective
Divalproex sodium	Amitriptyline	Lisinopril	Clonidine ^a	Lamotrigine
Sodium valproate	Venlafaxine	α-Agonists	Antidepressants/SSRI/SSNRI	Probably ineffective
Topiramate	β-Blockers	Guanfacine ^a	Fluoxetine	Clomipramine ^a
β-Blockers	Atenolol ^a	Angiotensin receptor blockers	Fluvoxamine ^a	Possibly ineffective
Metoprolol	Nadolol ^a	Candesartan	Antiepileptic drugs	Acebutolol ^a
Propranolol	Triptans (MRM ^b)	Antiepileptic drugs	Gabapentin	Clonazepam ^a
Timolol ^a	Naratriptan ^b	Carbamazepine ^a	Antithrombotics	Nabumetone ^a
Triptans (MRM ^b)	Zolmitriptan ^b	Antihistamines	Acenocoumarol	Oxcarbazepine
Frovatriptan ^b		Cyproheptadine	Coumadin	Telmisartan
		β-Blockers	Picotamide	
		Nebivolol	β-Blockers	
		Ca ⁺⁺ blockers	Bisoprolol ^a	
		Nicardipine ^a	Pindolol ^a	
			Ca ⁺⁺ blockers	
			Nifedipine ^a	
			Nimodipine	
			Verapamil	
			Carbonic anhydrase inhibitor	
			Acetazolamide	
			Direct vascular smooth muscle relaxants	
			Cyclandelate	
			TCA	
			Protriptyline ^a	

Abbreviations: ACE = angiotensin-converting-enzyme; Ca⁺⁺ blockers = calcium channel blockers; MRM = menstrually related migraine; SSNRI = selective serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant.

^a Classification based on original guideline and new evidence not found for this report.

^b For short-term prophylaxis of MRM.

Neurology[®]

Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society

Neurology 2013;80;871

DOI 10.1212/WNL.0b013e318287dc4e

This information is current as of February 25, 2013

Updated Information & Services

including high resolution figures, can be found at:
<http://n.neurology.org/content/80/9/871.full>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2013 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

